Koasteam, Approval for Clinical Trial Phase 3 Protocol Amendment of Neuronata-RJ
[Asia Economy Reporter Oh Ju-yeon] Corestem announced on the 27th that it has received approval from the Ministry of Food and Drug Safety for changes to the domestic Phase 3 clinical trial plan of Neuronata-AL injection.
The company stated, "We have received approval for changes to the clinical trial plan, including the administration period, efficacy evaluation variables, and the number of subjects."
Hot Picks Today
"Two Eggs for Breakfast, My Protein" The Betrayal of Soft-Boiled Eggs...In July, Always Eat Them Hard-Boiled
- "I Spent 28 Billion Won and Even Received My Son's Plasma to Avoid Aging... But Was Diagnosed with an Incurable Disease"
- Samsung Electronics to Sell KRW 344.5 Billion in Treasury Shares for DX Division Employee Compensation
- "Severity of Social Harm" - Local Official Sentenced to Death in China for Accepting 500 Billion Won in Bribes Over 30 Years
- "Do Not Mess with Her" Warning... Belgium Steps Up Against Trump’s Continued Mockery
The target disease is amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
